During the past decade, Centre ophtalmologique Maison Rouge conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centre ophtalmologique Maison Rouge" are "Age Related Macular Degeneration" (1 trials), "Diabetes Mellitus" (1 trials), "Diabetic Macular Edema" (1 trials), "Diabetic Retinopathy" (1 trials) and "Geographic Atrophy" (1 trials). Many other conditions were trialed in "Centre ophtalmologique Maison Rouge" in a lesser frequency.

Most popular intervention types in "Centre ophtalmologique Maison Rouge" are "Drug" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "APL-2" (1 trials), "Data collection up to 1 year" (1 trials), "PEGCETACOPLAN (APL-2)" (1 trials), "Questionnaire" (1 trials) and "Ranibizumab 0.5mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre ophtalmologique Maison Rouge" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Centre ophtalmologique Maison Rouge". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Centre ophtalmologique Maison Rouge, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre ophtalmologique Maison Rouge, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".